Böbrek nakli yapılan hastalarda proteinüri sıklığı ve nedenleri

Yıl 2016, Cilt: 2 Sayı: 1, 4 - 11, 08.03.2016

Alirıza Ünsal , Mehmet Tanrısev Cemalettin Oluç

Öz

Amaç: Bu çalışmada böbrek nakli yapılan hastalarda proteinüri sıklığı ve nedenleri araştırıldı. Hastalar ve yöntemler: Çalışmaya böbrek nakli yapılan ve Tepecik Eğitim ve Araştırma Hastanesi Nefroloji Kliniği’nde takip edilen 100 hasta (68 erkek, 32 kadın; ort. yaş 42.1±11.4 yıl; dağılım 17-68 yıl) dahil edildi. Hastaların demografik özellikleri, biyokimyasal verileri, immünsüpresif tedavileri ve biyopsi sonuçları poliklinik takip dosyalarından retrospektif olarak kaydedildi.

Bulgular: 1000 mg/gün üzerindeki değerler proteinüri olarak tanımlandı ve 36 hastada proteinüri saptandı. Bu 36 hastanın 16’sına biyopsi yapıldı. Akut rejeksiyonlar proteinürinin önde gelen nedenlerindendi. Ayrıca, proteinüri düzeyi 1000 mg/gün’ün altında olan 64 hastanın 21’ine renal biyopsi uygulandı. Bu grupta nonspesifik biyopsi sonuçları en sık rastlanan bulgulardı. İmmünsüpresif ilaç kullanımı açısından 1000 mg/gün’den fazla proteinürisi olan hasta oranları benzerdi. Böbrek nakli yapılan hastalarda proteinüri sıklılığı %36 idi. Demografik veriler açısından gruplar arasında anlamlı farklılık yoktu.

Sonuç: Proteinüri düzeyleri daha yüksek olan hastalarda akut rejeksiyon en yaygın biyopsi sonucuydu. Beklenenin tersine, immünsüpresif tedavinin mTOR inhibitörlerinde anlamlı proteinüri sıklığı gözlenmedi.

Anahtar Kelimeler

İmmunsüpresif tedavi, böbrek nakli, proteinüri

Kaynakça

• Fernández-Fresnedo G, Plaza JJ, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004;19:47-51.
• Amer H, Fidler ME, Myslak M, Morales P, Kremers WK, Larson TS, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007;7:2748-56.
• Fernández-Fresnedo G, Escallada R, Rodrigo E, De Francisco AL, Cotorruelo JG, Sanz De Castro S, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002;73:1345-8.
• Ibis A, Altunoglu A, Akgül A, Usluogullari CA, Arat Z, Ozdemir FN, et al. Early onset proteinuria after renal transplantation: a marker for allograft dysfunction. Transplant Proc 2007;39:938-40.
• Park JH, Park JH, Bok HJ, Kim BS, Yang CW, Kim YS, et al. Persistent proteinuria as a prognostic factor for determining long-term graft survival in renal transplant recipients. Transplant Proc 2000;32:1924.
• Roodnat JI, Mulder PG, Rischen-Vos J, van Riemsdijk IC, van Gelder T, Zietse R, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001;72:438-44.
• Sancho A, Gavela E, Avila A, Morales A, Fernández- Nájera JE, Crespo JF, et al. Risk factors and prognosis for proteinuria in renal transplant recipients. Transplant Proc 2007;39:2145-7.
• Suárez Fernández ML, G-Cosío F. Causes and consequences of proteinuria following kidney transplantation. Nefrologia 2011;31:404-14.
• Myslak M, Amer H, Morales P, Fidler ME, Gloor JM, Larson TS, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006;6:1660-5.
• First MR, Vaidya PN, Maryniak RK, Weiss MA, Munda R, Fidler JP, et al. Proteinuria following transplantation. Correlation with histopathology and outcome. Transplantation 1984;38:607-12.
• Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol 2008;4:446-57.
• Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003;35:52-7.
• Diekmann F, Fritsche L, Neumayer HH, Budde K. Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients. Kidney Blood Press Res 2004;27:186-90.
• Dittrich E, Schmaldienst S, Soleiman A, Hörl WH, Pohanka E. Rapamycin-associated post- transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215-20.
• Diekmann F, Gutiérrez-Dalmau A, López S, Cofán F, Esforzado N, Ricart MJ, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant 2007;22:2316-21.
• Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006;6:429-33.
• Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007;2:326-33.
• Mainra R, Mulay A, Bell R, Karpinski J, Hoar S, Knoll G, et al. Sirolimus use and de novo minimal change nephropathy following renal transplantation. Transplantation 2005;80:1816.
• Knoll GA. Proteinuria in kidney transplant recipients: prevalence, management. Am J Kidney Dis 2009;54:1131-44.
• Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. Angiotensin- converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006;17:889-99.
• Peddi VR, Dean DE, Hariharan S, Cavallo T, Schroeder TJ, First MR. Proteinuria following renal transplantation: correlation with histopathology and outcome. Transplant Proc 1997;29:101-3.
• Kim HC, Park SB, Lee SH, Park KK, Park CH, Cho WH. Proteinuria in renal transplant recipients: incidence, cause, and prognostic importance. Transplant Proc 1994;26:2134-5.
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis 2002;39:1-266.
• Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100.
• Torng S, Rigatto C, Rush DN, Nickerson P, Jeffery JR. The urine protein to creatinine ratio (P/C) as a predictor of 24-hour urine protein excretion in renal transplant patients. Transplantation 2001;72:1453-6.
• Rodrigo E, Piñera C, Ruiz JC, Fernández-Fresnedo G, Escallada R, Herráez I, et al. Quantitation of 24-hour urine protein excretion in kidney transplant patients by the use of protein to creatinine ratio. Transplant Proc 2003;35:702.
• Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80:1198-203.
• Mreich E, Coombes JD, Rangan GK. Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells. Transplantation 2007;83:105-7.
• Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002;62:311-8.
• Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52.
• van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006;70:1355-7.
• Halimi JM, Laouad I, Buchler M, Al-Najjar A, Chatelet V, Houssaini TS, et al. Early low-grade proteinuria: causes, short-term evolution and long- term consequences in renal transplantation. Am J Transplant 2005;5:2281-8.
• Chailimpamontree W, Dmitrienko S, Li G, Balshaw R, Magil A, Shapiro RJ, et al. Probability, predictors, and prognosis of posttransplantation glomerulonephritis. J Am Soc Nephrol 2009;20:843-51.
• Rose BD, Post TW. Measurement of urinary protein excretion. Up to date 17.1. Available at: http://www. utdol.com. [Accessed: January 13, 2009].
• Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007;27:287-93.
• Pérez Fontán M, Rodríguez-Carmona A, García Falcón T, Valdés F. Early proteinuria in renal transplant recipients treated with cyclosporin. Transplantation 1999;67:561-8.